Orforglipron API
COA 29 Inquiries
2212020-52-3
Pharmaceutical Grade
99%
南通港
100g;1000g;10000g
2026-04-16
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOrforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.CertificatesBasic Info-
Product Name:
Orforglipron
Other Name:1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833
CAS No.:2212020-52-3
Molecular Formula:C48H48F2N10O5
InChIKeys:USUWIEBBBWHKNI-BBGRWQLENA-N
Molecular Weight:882.97
EC Number:278-636-5
Color/Form:Off-white to light yellow
Categories:
Characteristics-
Density:
1.50±0.1 g/cm3(Predicted)
PKA:7.33±0.20(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Location:
RONGSHENG BEIYUANDAJIE 9, LICHENG DISTRICT,JINAN, SHANDONG CHINA
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Inquiry History29 Inquiries
Country Product Purchase Quantity Date Posted 
Bulgaria
orforglipron
1 KG Aug 27, 2025 
United Kingdom
Orforglipron
1000 MT Oct 17, 2026 
Austria
Orforglipron
1000 MT Jun 12, 2026 
Switzerland
Orforglipron
10 MG Apr 25, 2026 
United States
Orforglipron
20 G Apr 3, 2026
United States
Orforglipron
10 G Mar 29, 2026
United States
oforglipron
3 KG Jul 4, 2025
United Kingdom
Orforglipron
1 G Jul 9, 2026 
Belgium
Orforglipron
1 G Jun 14, 2026 
Puerto Rico
Orforglipron
1 G Mar 2, 2026
United States
Orforglipron
10 G Oct 24, 2025
United States
Orforglipron
1 G Sep 30, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
orforglipron
1 MT Sep 20, 2025
United States
Orforglipron
1 KG Apr 18, 2025 
Canada
LY-3502970
10 G Feb 26, 2026
Switzerland
Orforglipron
100 G Sep 25, 2026 
India
orforglipron
1.00 G Jul 16, 2026
United States
orforglipron
10 G Apr 20, 2026 Post an enquiry for this product
